Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
64.34
-2.77 (-4.13%)
At close: Jun 25, 2026, 4:00 PM EDT
64.34
0.00 (0.00%)
After-hours: Jun 25, 2026, 5:02 PM EDT

Tarsus Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Tarsus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $94.11. The average 1-year stock price forecast is 46.27% higher than the current stock price, while the lowest is $88 (+36.77%) and the highest is $100 (+55.42%).

Price Target: $94.11 (+46.27%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$88$94.11$95$100
Change+36.77%+46.27%+47.65%+55.42%
* Price targets were last updated on May 27, 2026.

Analyst Ratings

The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy778888
Buy111111
Hold100000
Sell000000
Strong Sell000000
Total989999

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
William Blair
William Blair
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 3, 2026
Mizuho Securities
Mizuho Securities
Buy
Reiterates
$100
BuyReiterates$100+55.42%May 27, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$88
BuyMaintains$88+36.77%May 26, 2026
Barclays
Barclays
Buy
Maintains
$100
BuyMaintains$100+55.42%May 15, 2026
LifeSci Capital
LifeSci Capital
Buy
Reiterates
$95
BuyReiterates$95+47.65%May 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
696.36M
from 451.36M
Increased by 54.28%
Revenue Next Year
904.52M
from 696.36M
Increased by 29.89%
EPS This Year
-0.59
from -1.59
EPS Next Year
2.87
from -0.59
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
57.03M25.82M17.45M182.95M451.36M696.36M
Revenue Growth
--54.73%-32.42%948.62%146.71%54.28%
Gross Profit
13.24M-17.76M-34.46M116.74M356.35M647.96M
Gross Margin
23.22%-68.81%-197.50%63.81%78.95%93.05%
Operating Income
-12.16M-62.71M-143.16M-120.57M-70.97M-29.57M
Net Income
-13.83M-62.09M-135.89M-115.55M-66.42M-28.48M
EPS
-----1.59-0.59
Free Cash Flow
4.74M-27.35M-74.49M-50.48M-164.00K-55.15M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High704.3M
Avg696.4M
Low688.0M

Revenue Growth

Revenue Growth202620272028
High
56.0%
Avg
54.3%
Low
52.4%

EPS Forecast

EPS202620272028
High-
Avg-0.59
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-